2-碘-4-硝基苯甲醚 | 5399-03-1

• 物质功能分类: 化学试剂 - 有机试剂 - 醚类
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-碘-4-硝基苯甲醚
• 中文别名: 2-碘基-4-硝基苯甲醚
• 英文名称: 2-iodo-1-methoxy-4-nitrobenzene
• 英文别名: 2-iodo-4-nitroanisole
• CAS: 5399-03-1
• 化学式: C₇H₆INO₃
• 分子量: 279.034
• InChiKey: KBQBNJHOTNIGDD-UHFFFAOYSA-N

物化性质

• 熔点：
  96-98°C
• 沸点：
  343.3±27.0 °C(Predicted)
• 密度：
  1.893±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  55
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2909309090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Iodo-4-ntiroanisole
Synonyms: 2-Iodo-1-methoxy-4-nitrobenzene

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Iodo-4-ntiroanisole
CAS number: 5399-03-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H6INO3
Molecular weight: 279.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen Iodide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-碘-4-硝基苯甲醚 在 tin(ll) chloride 作用下， 生成 3-碘-4-甲氧基苯胺
  参考文献：
  名称：

  氯化吡咯与一些取代的苯胺反应的动力学。第6部分。4-取代和3,4-二取代的苯胺

  摘要：

  已经测量了氯化吡咯与以下取代的苯胺在乙腈中的反应的Arrhenius参数：4-X-（X = F，Cl，Br，I，Me或OMe）；3,4-X 2-（X = Cl，Br，Me或OMe）; 4-X-3-硝基-（X = F，Cl或Me）; 3-X-4-甲氧基-（X = F，Cl，Br或I）; 3-氟-4-硝基-; 和3,4,5-三甲氧基苯胺。在3,4-二取代系列中，两个甲基对活化自由能的影响是严格加和的，但对于其余部分，测得的速率常数要大于在假定加和性的情况下测得的速率常数。根据过渡态在反应坐标上的位置来合理化结果。

  DOI：

  10.1039/p29800000832
• 作为产物：
  描述：

  2-硝基苯甲醚 在 盐酸 、 tin 、 碘 、 硝酸 作用下， 生成 2-碘-4-硝基苯甲醚
  参考文献：
  名称：

  Robinson, Journal of the Chemical Society, 1916, vol. 109, p. 1087

  摘要：

  DOI：

文献信息

• [EN] COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS<br/>[FR] COMPOSÉS POUR INHIBER LA PROLIFÉRATION CELLULAIRE DANS LES CANCERS INDUITS PAR L'EGFR
  申请人：ARIAD PHARMA INC

  公开号：WO2013169401A1

  公开（公告）日：2013-11-14

  The invention features compounds, pharmaceutical compositions and methods for treating patients who have an EGFR-driven cancer of Formula (I), wherein the variables are as defined herein.

  这项发明涉及化合物、药物组合物和治疗EGFR驱动的Formula (I)癌症患者的方法，其中变量如本文所定义。
• Efficient one-pot transformation of aminoarenes to haloarenes using halodimethylisulfonium halides generated in situ
  作者：Woonphil Baik、Wanqiang Luan、Hyun Joo Lee、Cheol Hun Yoon、Sangho Koo、Byeong Hyo Kim

  DOI：10.1139/v05-026

  日期：2005.3.1

  Halodimethylsulfonium halide 1, which is readily formed in situ from hydrohaloic acid and DMSO, is a good nucleophilic halide. This activated nucleophilic halide rapidly converts aryldiazonium salt prepared in situ by the same hydrohaloic acid and nitrite ion to aryl chlorides, bromides, or iodides in good yield. The combined action of nitrite ion and hydrohaloic acid in DMSO is required for the direct transformation of aromatic amines, which results in the production of aryl halides within 1 h. Substituted compounds with electron-donating or -withdrawing groups or sterically hindered aromatic amines are also smoothly transformed to the corresponding aromatic halides. The only observed by-product is the deaminated arene (usually <7%). The isolated aryldiazonium salts can also be converted to the corresponding aryl halides using 1. The present method offers a facile, one-step procedure for transforming aminoarenes to haloarenes and lacks the environmental pollutants that usually accompany the Sandmeyer reaction using copper halides. Key words: aminoarenes, haloarenes, halodimethylsulfonium halide, halogenation, amination.

  卤二甲基亚砜卤化物1是一种良好的亲核卤化物，可在现场由氢卤酸和二甲亚砜形成。这种活化的亲核卤化物迅速将由相同的氢卤酸和亚硝酸根在现场制备的芳基重氮盐转化为芳基氯化物、溴化物或碘化物，收率较高。在DMSO中，亚硝酸根和氢卤酸的联合作用是直接转化芳香胺的必要条件，从而在1小时内产生芳基卤化物。带有电子给体或吸引基团或有立体位阻的芳香胺的取代化合物也可顺利转化为相应的芳香卤化物。观察到的唯一副产物是去氨基芳烃（通常<7%）。孤立的芳基重氮盐也可以使用1转化为相应的芳基卤化物。该方法提供了一种简便的、一步法的程序，用于将氨基芳烃转化为卤代芳烃，并且不伴随通常伴随使用铜卤化物进行桑迈尔反应的环境污染物。关键词：氨基芳烃，卤代芳烃，卤二甲基亚砜卤化物，卤化，胺化。
• MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS
  申请人：Combs Andrew Paul

  公开号：US20090286778A1

  公开（公告）日：2009-11-19

  The present invention relates to macrocyclic compounds of Formula I: or pharmaceutically acceptable salts thereof or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are JAK/ALK inhibitors useful in the treatment of JAK/ALK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.

  本发明涉及以下化学式I的大环化合物： 或其药用可接受盐或季铵盐，其中所述成员在此提供，并且它们的组成物和使用方法，这些JAK/ALK抑制剂在治疗JAK/ALK相关疾病中有用，例如炎症和自身免疫性疾病以及癌症。
• [EN] METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE<br/>[FR] PROCÉDÉS ET COMPOSÉS POUR LE TRAITEMENT D'UNE MALADIE GÉNÉTIQUE
  申请人：DESIGN THERAPEUTICS INC

  公开号：WO2021158707A1

  公开（公告）日：2021-08-12

  The present disclosure relates to compounds and methods for modulating the expression of dmpk, and treating diseases and conditions in which dmpk plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence CAG or CTG; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence CAG or CTG; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.

  本公开涉及化合物和方法，用于调节dmpk的表达，并治疗dmpk发挥积极作用的疾病和病况。该化合物可以是一种转录调节分子，具有第一末端、第二末端和寡聚骨架，其中：a）第一末端包括一种DNA结合基团，能够非共价结合到核苷酸重复序列CAG或CTG；b）第二末端包括结合到调节分子的蛋白结合基团，该调节分子调节包含核苷酸重复序列CAG或CTG的基因的表达；c）寡聚骨架包括连接第一末端和第二末端的连接物。
• Oxidative Iodination of Deactivated Arenes in Concentrated Sulfuric Acid with I₂/NaIO₄and KI/NaIO₄Iodinating Systems
  作者：Lech Skulski、Lukasz Kraszkiewicz、Maciej Sosnowski

  DOI：10.1055/s-2006-926374

  日期：——

  from NaIO 4 and either I 2 or KI in concentrated H 2 SO 4 (minimum 95% by weight). In general a small excess of the dark brown iodinating solution was used (1.1/1.5 equivalents, for nitrobenzene two equivalents was required). The iodinations were conducted at 25-30 °C with a reaction time of 1-2 hours using either a 'direct' or an 'inverse' method of aromatic iodination to give mono- or diiodinated pure

  用强亲电 I + 试剂对失活的芳烃进行单碘化或二碘化，这些试剂由 NaIO 4 和 I 2 或 KI 在浓 H 2 SO 4 中制备（至少 95% 重量）。通常使用稍微过量的深棕色碘化溶液（1.1/1.5 当量，对于硝基苯需要两个当量）。碘化在 25-30 °C 下进行，反应时间为 1-2 小时，使用芳香族碘化的“直接”或“反向”方法以 31-91% 的优化产率得到单碘化或二碘化纯产物。